Side-by-Side Comparison
Mounjaro vs Zepbound
Same active ingredient (tirzepatide), different FDA-approved indications. Mounjaro for T2 diabetes; Zepbound for chronic weight management.
Same active ingredient (tirzepatide), different FDA-approved indications. Mounjaro for T2 diabetes; Zepbound for chronic weight management.
| Mounjaro | Zepbound | |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| Approved indication | Type 2 diabetes (T2DM) | Chronic weight management; OSA in adults with obesity |
| Initial FDA approval | May 2022 | November 2023 |
| Dose forms | Prefilled pen (multi-dose) | Single-dose vial + prefilled pen |
| Dose range | 2.5–15 mg weekly | 2.5–15 mg weekly |
| Insurance coverage | Often covered for T2DM with prior auth | Often covered for obesity with BMI documentation + step therapy |
| LillyDirect cash pricing | Standard pen pricing | Reduced cash-pay on single-dose vials |
Mounjaro and Zepbound are the same active drug — tirzepatide — packaged and labeled separately for different FDA-approved uses. The molecule, dose, mechanism of action, and side-effect profile are identical. The split is regulatory: FDA approves a manufacturer's drug for a specific indication, and Lilly chose to brand the same molecule under two names. Some prescriptions can be substituted clinically but the labeling and insurance pathways are different.
Many commercial plans cover Mounjaro for type 2 diabetes after step therapy through metformin and sometimes other agents. Many plans cover Zepbound for obesity with BMI documentation (BMI ≥30, or ≥27 with a weight-related comorbidity per the FDA label). Medicare Part D historically excluded obesity drugs but expanded Zepbound coverage for OSA in adults with obesity in 2025. Verify your specific plan's coverage rules.
Both list at approximately $1,000–$1,200/month before insurance. Eli Lilly's LillyDirect program (self-pay channel) offers reduced cash prices on Zepbound single-dose vials, which made the drug more accessible to cash-pay patients. Mounjaro pricing via LillyDirect varies by dose strength.
Compounded tirzepatide is the same active molecule but is prepared by 503A licensed compounding pharmacies or 503B FDA-registered outsourcing facilities; it is not FDA-approved as a drug product and is not Mounjaro or Zepbound. Telehealth providers (including TirzepatideReview.com's #1 pick NexLife) typically dispense compounded versions at substantially lower cost than the brand-name products. Discuss with your clinician.
Identical for both brands since they contain the same active molecule: GI side effects (nausea most common), risk of pancreatitis, black-box warning for thyroid C-cell tumors (rodent studies). Contraindications: personal or family history of MTC, MEN 2, severe gastrointestinal disease, pregnancy, breastfeeding.
Are Mounjaro and Zepbound the same drug?
Yes — both contain tirzepatide, the same active molecule manufactured by Eli Lilly. The FDA approved them under different brand names for different indications: Mounjaro for type 2 diabetes (2022); Zepbound for chronic weight management (2023) and obstructive sleep apnea in adults with obesity (2024).
Can I take Mounjaro for weight loss?
Mounjaro is FDA-approved only for type 2 diabetes. Off-label use for weight loss occurs but insurance typically denies obesity coverage for Mounjaro because Zepbound is the on-label option. Discuss with a licensed clinician.
Which is cheaper, Mounjaro or Zepbound?
Cash prices are similar at approximately $1,000–$1,200/month. Lilly's LillyDirect program offers reduced cash pricing on Zepbound single-dose vials, which is often the lowest cash-pay option for the brand-name product. Compounded tirzepatide via telehealth providers like NexLife is substantially less expensive ($186/month at NexLife's 12-month plan).
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000